Home › Compare › SCTTF vs ABBV
SCTTF yields 4.02% · ABBV yields 3.06%● Live data
📍 SCTTF pulled ahead of the other in Year 7
Combined, SCTTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SCTTF + ABBV for your $10,000?
Scott Technology Limited, designs, manufactures, sells, and services automated and robotic production lines, and processes for various industries in New Zealand and internationally. The company operates through New Zealand manufacturing, Australia Manufacturing, Americas Manufacturing, Europe Manufacturing, and China Manufacturing segments. It offers rock crushers, pulverisers, ringmills, and reference materials for mining companies and laboratories under the Rocklabs brand name; bandsaw safety equipment for meat processing under the BladeStop brand name; and new and refurbished industrial robots under the RobotWorx brand name. Further, the company provides automated guided vehicles under the Transbotics brand name; palletising, conveying, and warehouse automation under the ALVEY brand name; and an industrial software under the MAESTRO+ brand name. It serves appliances, materials handling and logistics, meat processing, mining, and other industrial automation industries. Scott Technology Limited was founded in 1913 and is headquartered in Dunedin, New Zealand.
Full SCTTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.